AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05647720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distalization without upper third molars extraction
Description: The maxillary first molars were distalized , without extracting upper third molars, using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
Study NCT04386005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Device
Description: The Dexcom G7 Glucose Monitoring System (San Diego, CA) reports continuous interstitial blood glucose concentrations every 5 minutes, does not require calibration, and involves only 1 needle stick to place the sensor. The manufacturer recommends that a single sensor may be used for up to 10 days. The Dexcom G7 system is the only FDA approved CGM system for children (age >2 years).
Study NCT06543420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral reconstruction
Description: In lateral reconstruction group, lateral reconstruction is performed by suturing the levator ani muscle to the prostatic collateral ligament and fascia to strengthen the lateral posterior support structure.
Study NCT06543420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior reconstruction
Description: In posterior group, prior to completion of the operation, the posterior fibrous tissues of the sphincter are joined to the residual Denonvilliers fascia on the posterior bladder wall 1-2 cm cephalad and dorsally to the new bladder neck.
Study NCT04803747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA)
Description: TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
Study NCT04803747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9 % Saline)
Description: Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
Study NCT05688553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexi-bar
Description: two groups, experimental group intervention Flexi-bar with balance and strength training
Study NCT05688553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance and strength training
Description: the control group intervention only balance and strength training
Study NCT04763616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
Study NCT04763616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
Study NCT04893525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.
Study NCT05508269 — intervention group
Intervention type: GENETIC
Intervention: quantitative polymerase chain reaction(QPCR) for four genes
Description: quantitative polymerase chain reaction(QPCR) for four genes
Study NCT05508269 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac biopsy, blood sampling
Description: In the studied thirteen peripheral blood subjects, five milliliters blood samples were taken from each patient in potassium EDTA tubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators. All studied thirteen cardiac tissue subjects were underwent cardiac biopsy after PCI in order to take two specimens from the left ventricle using judkin right seven french catheters for femoral access and cardiac bioptome 2.3 mm wide. All cardiac specimens were collected in cryotubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators.
Study NCT05789576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTAMA (tapinarof) cream, 1%
Description: VTAMA (tapinarof) cream, 1% applied topically once daily
Study NCT05678283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]CC-90010
Description: Specified dose on specified days
Study NCT05678283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90010
Description: Specified dose on specified days
Study NCT05655923 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ozonized olive oil
Description: ozonized oil will be mixed with xenograft in group II and Group III
Study NCT05655923 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: xenograft bone substitute
Description: Xenograft bone substitutes in all Groups
Study NCT05655923 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: xenograft bone substitute
Description: Xenograft bone substitutes in all Groups
Study NCT05570812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (4-week ramp, 4-week steady dosing)
Study NCT05570812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: (4-week ramp, 4-week steady dosing)
Study NCT05144945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine (RIV4)
Description: Solution for intramuscular injection
Study NCT05144945 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent inactivated influenza vaccine (IIV4)
Description: Suspension for intramuscular injection
Study NCT05878912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
Study NCT05933889 — intervention group
Intervention type: GENETIC
Intervention: Molecular Analysis
Description: Germline and circulating tumour DNA analysis of buccal/ blood samples and molecular analysis of primary and recurrent tumour tissue samples
Study NCT05933889 — intervention group
Intervention type: OTHER
Intervention: Radiomic/ Morphological analysis
Description: Radiomic analysis and assessment of morphological features of pre-operative CT/ MRI imaging in patients who have undergone TORS for primary oropharyngeal cancer.
Study NCT05525507 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conditioning and Stem cell infusion
Description: Patients will undergo a conditioning with TLI and ATG, followed by infusion of hematopoietic stem cells from the same HLA-identical donor that provided the original kidney
Study NCT06231810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Description: Tactile stimuli of differing magnitudes will be applied
Study NCT04801043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107
Description: XNW4107 250mg IV over 60 minutes as a single dose
Study NCT04801043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin
Description: 500mg/500mg IV over 60 minutes as a single dose
Study NCT04801043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose~Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose
Study NCT05689008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs treatment
Description: Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
Study NCT05980897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naming treatment
Description: In this alternating treatment single-subject experimental design study, the investigators will alternate between two treatment conditions, i.e., two different types of stimulus items: those that are consistently reported as successful IS prior to treatment (sIS items) and those that are consistently reported as unsuccessful IS prior to treatment (uIS items). The treatment will be computerized to ensure consistency of presentation, timing, and cues across participants.~For each stimulus presentation, the treatment hierarchy will proceed as follows:~1. Name the picture independently~2. Name the picture with a written cue~3. Repeat the name of the picture~4. Name the picture after a 5 second delay Each participant will be trained on a set of 40 items chosen specifically for them based on initial/baseline testing.
Study NCT06058611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: Cognitive stimulation through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
Study NCT06058611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulating leisure activities
Description: Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (\< 30 min, 30min-1 hour, 1-2 hours, > 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life.
Study NCT05857800 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Analysis of dynamic changes of lung cancer microenvironment in neoadjuvant therapy using bio-omics information collected in clinical trials.
Study NCT04710199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc experimental group
Description: 300-milligram dose of the drug two times daily , oral way. During 14 days.
Study NCT04710199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.
Study NCT05383339 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: - 56mL blood collected additionally to routine care
Study NCT04829123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen
Study NCT04829123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen
Study NCT04970290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Definisse threads free floating and definisse threads double needle
Description: Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30
Study NCT06404853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Manna
Description: Administration is by the oral route according to weight at a dosage of 1 g/kg/day, dissolved in a glass of water, up to a maximum of 30 g. Administration should be repeated every 24 h for 8 weeks, accompanied by plenty of hydration.~In case an effective dosage is achieved (evacuation within 72 h) it will be maintained until the end of the study. If evacuation has not occurred after 72 h, evacuative enema and increased dosage to 1.5 g/kg/day will be indicated. If further evacuative enema is needed, product administration will be discontinued and classical polyethylene glycol therapy will be started as per guidelines.
Study NCT06477861 — intervention group
Intervention type: OTHER
Intervention: calculation of the elastic power of the lung in case of the ARDS and corolating with the severity index of Berline definition of ARDS in respect to mortality and severity
Description: calculation of variables of the elastic power of the lung from the lung pressures on the ventilator : Elastic power = 0.098 \* tidal volume \* respiratory rate \* 1/2(PEEP+Pplat)
Study NCT05584605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill training
Description: The intervention will be delivered based on the initial exercise testing and graded based by increasing the duration, speed and/or altitude of the treadmill training.
Study NCT05584605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: Interventions, such as stretching, relaxation, passive soft-tissue technics (excl. manipulation) that do not elevate the heart rate above 20HRR
Study NCT05445063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous iPSC-derived RPE
Description: Autologous transplantation of iPSC-derived RPE
Study NCT05994469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Copenhagen Adduction Exercise
Description: The CAE is performed by side-lying on the floor with the dominant lower limb supported in the air by a teammate, the hip is adducted until the body forms a straight line from the ankles to the shoulders (concentric phase), then the player is instructed to lower the body slowly (eccentric phase) until reaching the floor to start the next repetition.
Study NCT05553197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 20 sessions of face-to-face, individual CBT
Study NCT05553197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 20 sessions of face-to-face, individual CBT
Study NCT05553197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA)
Description: Two four-week blocks of twice daily ecological momentary assessment (EMA) of symptoms and inter-session processes
Study NCT00003564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
Study NCT00003564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine Hydrochloride
Description: Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses.
Study NCT04810468 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anthropometric measurment
Description: Anthropometric measurment used to asses the wheight in kelogram and asses height in cetemeter and also asses BMI
Study NCT04883684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal health wallet service for Chronic Patients in Emergency Department
Description: Patients(caregivers) will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
Study NCT05535400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical-Psychological Integrative Intervention
Description: The PPI intervention will include eight weekly online group sessions (with each session lasts for 60-90 minutes). At the beginning of each online group meeting, the intervention provider will use motivational interviewing techniques to promote participants' adherence to the physical activity program. And the content of the intervention includes eight different sessions, including Session 1- Orientation and engagement, Session 2- Awareness and Acceptance; Session 3- Non-judgement; Session 4- Stay present and let go; Session 5- Our thoughts are not real \& Response without reacting; Session 6- Empowerment of self-management and discuss pain management; Session 7- Seek out pleasant things and social support and Session 8- Review the intervention and end the programme.
Study NCT05535400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brief online didactic education
Description: Participants in the control group will receive a short video call (approximately 20 minutes each week for eight weeks) from the trained research assistant, i.e., RA 2 to provide general physical and psychological suggestions (e.g., encouragement of performing physical activities, and communication skills with family members/friends, and engagement in the community life). This is to control the contact effects of the PPI intervention.
Study NCT04636671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Per-protocol methylprednisolone administration and tapering (see arm description)
Study NCT04636671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Per-protocol dexamethasone administration (see arm description)
Study NCT06225440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Levagen+® Palmitoylethanolamide (PEA)
Description: Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.
Study NCT06225440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.
Study NCT05613049 — intervention group
Intervention type: OTHER
Description: If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
Study NCT04857567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSC program (Three Self-Commitment program)
Description: 1. Self-Competence program~   - A program for residents who experience exhaustion due to the spirit of volunteerism and high expectations of therapeutic competency in the case of experiencing a decrease in personal achievement.~2. Self-Care program~   - A program to help individuals who experience dehumanization due to emotional suppression and develop exhaustion in the process of suppressing emotions to protect themselves from excessive feelings of compassion experienced in the medical scene~3. Self-Compassion program - A program for residents who experience emotional burnout and exhaustion due to pressure of failure because medical professionals should be competent and excellent
Study NCT06509620 — intervention group
Intervention type: OTHER
Intervention: Fatigue severity scale
Description: fatigue severity scale is a unidimensional, nine-item questionnaire capturing information on the impact and severity of fatigue. Participants rated the 9-items on a 7-point, Likert-type scale with anchors of strongly disagree (1) and strongly agree (7) based on the previous week. The overall score is an average of the individual item scores and can range between 1 and 7.
Study NCT05389995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium citrate
Description: 7 days potassium citrate followed by 24 hour urine collection
Study NCT05389995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystal light
Description: 7 days crystal light followed by 24 hour urine collection
Study NCT05389995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium citrate + crystal light
Description: 7 days potassium citrate + crystal light followed by 24 hour urine collection
Study NCT05329168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonabacase (LSVT-1701)
Description: 4.5 or 6.0 mg/kg IV once daily for 4 days
Study NCT06031636 — intervention group
Intervention type: DRUG
Intervention: Oncolytic Adenovirus H101
Description: The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
Study NCT06031636 — intervention group
Intervention type: DRUG
Intervention: Programmed death receptor-1 inhibitor
Description: The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
Study NCT06177951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICU Discharge Passport
Description: The NICU discharge passport contains a discharge checklist highlighting important go-to information for infants (feeding plan, medications, pharmacy information, pediatrician, and follow ups post-discharge). It also provides key anticipatory guidance for newborns.